CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 59 enrolled
Drug / intervention
Peginterferon alfa-2a [Pegasys]drug
Likely dose
Peginterferon alfa-2a [Pegasys] 180 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01787279
NCT01787279Phase 4Completed
CompareCT.gov

Expanded Access Programme of PEGASYS® (Peg Interferon Alpha-2a 40KD) in Patients With HBe-Ag-negative Chronic Hepatitis B

Hoffmann-La Roche·interventional·Posted Feb 8, 2013·Updated Jul 22, 2016

In Brief

A Phase 4 clinical trial evaluating Peginterferon alfa-2a [Pegasys] for Hepatitis B, Chronic. Completed, enrolled 59 participants across 4 sites.

Detailed Summary

This is an expanded access programme to make Pegasys (peginterferon alfa-2a) available to patients with HBeAg-negative chronic hepatitis B in Morocco. Patients will receive Pegasys 180 mcg subcutaneously weekly for 48 weeks and efficacy and safety will be recorded during treatment and for 24 weeks of follow-up.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesMorocco
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 8, 2013
Enrollment StartJan 1, 2006
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.4 years ago

Interventions

Peginterferon alfa-2a [Pegasys]drug

180 mcg subcutaneously weekly, 48 weeks